Definium Reports Q1 2026 Earnings with Key Clinical Trial Updates
Definium provided updates on its clinical trials for DT120 ODT in treating major depressive disorder and generalized anxiety disorder. The company has completed enrollment in multiple Phase III studies, including EMERGE, VOYAGE, and PANORAMA, with topline results expected this quarter or early Q3.
Topics: anxiety autism spectrum disorder depression pharmaceuticals